S. Fisher

发表

Kinetic Comparison of the Specificity of the Vancomycin Resistance Kinase VanS for Two Response Regulators, VanR and PhoB†

Barry L. Wanner, Christopher T. Walsh, Stewart L. Fisher, 1996 .

Inhibitors of the bacterial cell wall biosynthesis enzyme MurC.

S. Fisher, F. Reck, S. Marmor, 2001, Bioorganic & medicinal chemistry letters.

Conservation of the structure and function of bacterial tryptophan synthases

A. Joachimiak, M. Endres, B. Nocek, 2019, IUCrJ.

The N-terminal Domain of RGS4 Confers Receptor-selective Inhibition of G Protein Signaling*

S. Muallem, E. Ross, P. Chidiac, 1998, The Journal of Biological Chemistry.

Targeted protein degradation and the enzymology of degraders.

S. Fisher, A. Phillips, 2018, Current opinion in chemical biology.

Evaluation of the Small-molecule BRD4 Degrader CFT-2718 in Small-cell Lung Cancer and Pancreatic Cancer Models

A. Nikonova, A. Deneka, D. Proia, 2021, Molecular Cancer Therapeutics.

Structural Characterization of Degrader-Induced Ternary Complexes Using Hydrogen-Deuterium Exchange Mass Spectrometry and Computational Modeling: Implications for Structure-Based Design.

A. Good, J. Patel, S. Fisher, 2021, ACS chemical biology.

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pK(a): antibacterial agents with an improved safety profile.

D. Ehmann, M. Cronin, A. A. Godfrey, 2012, Journal of medicinal chemistry.

Advances in Protein Degradation

S. Fisher, M. P. Castaldi, 2021, SLAS discovery : advancing life sciences R & D.

METALLOPEPTIDE DESIGN : TUNING THE METAL CATION AFFINITIES WITH UNNATURAL AMINO ACIDS AND PEPTIDE SECONDARY STRUCTURE

R. P. Cheng, B. Imperiali, S. Fisher, 1996 .

Cross-talk between the Histidine Protein Kinase VanS and the Response Regulator PhoB CHARACTERIZATION AND IDENTIFICATION OF A VanS DOMAIN THAT INHIBITS ACTIVATION OF PhoB*

C. Walsh, B. Wanner, S. Fisher, 1995 .

Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II: broad-spectrum antibacterial agents with reduced hERG activity.

C. Eyermann, D. Ehmann, M. Cronin, 2011, Journal of medicinal chemistry.

Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story.

C. Walsh, S. Fisher, Z Wu, 1996, Chemistry & biology.

Stereoselective synthesis and peptide incorporation of (S)-.alpha.-amino-(2,2'-bipyridine)-6-propanoic acid

B. Imperiali, S. Fisher, 1992 .

A conformational study of peptides with the general structure Ac-L-Xaa-Pro-D-Xaa-L-Xaa-NH2: spectroscopic evidence for a peptide with significant .beta.-turn character in water and in dimethyl sulfoxide

B. Imperiali, R. Moats, S. Fisher, 1992 .

Stereoselective Synthesis and Peptide Incorporation of (S)-α- Amino-(2,2′-bipyridine)-6-propanoic Acid.

B. Imperiali, S. Fisher, 1992 .

(S)-.alpha.-Amino-(2,2'-bipyridine)-6-propanoic acid: a versatile amino acid for de novo metalloprotein design

B. Imperiali, S. Fisher, 1991 .

CHAPTER 4:Narrow Spectrum Antibacterial Agents

P. Tonge, S. Fisher, Lauren A. Spagnuolo, 2017 .

Secreted Gaussia princeps Luciferase as a Reporter of Escherichia coli Replication in a Mouse Tissue Cage Model of Infection

S. McLeod, S. Fisher, Mingyu Liu, 2014, PloS one.

Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor

D. Ehmann, P. Ross, S. Fisher, 2012, Proceedings of the National Academy of Sciences.

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

D. Ehmann, P. Ross, S. Fisher, 2013, The Journal of Biological Chemistry.

The N-terminal Domain of RGS 4 Confers Receptor-selective Inhibition of G Protein Signaling

S. Muallem, E. Ross, P. Chidiac, 1998 .

High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics

R. Improgo, S. Fisher, R. Pollock, 2021, SLAS discovery : advancing life sciences R & D.

Translating slow-binding inhibition kinetics into cellular and in vivo effects.

Peter J Tonge, Virna J A Schuck, Zhiping You, 2015, Nature chemical biology.

Development of an AchillesTAG degradation system and its application to control CAR-T activity

Hannah J. Maple, M. Sowa, D. Proia, 2021 .

A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase.

S. Schreiber, A. Joachimiak, P. McCarren, 2017, Nature chemical biology.

Exploitation of structural and regulatory diversity in glutamate racemases

T. Lundqvist, Yafeng Xue, S. Fisher, 2007, Nature.

An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in β-Cell Protection.

B. Wagner, N. Morgan, S. Richardson, 2016, ACS chemical biology.

Glutamate racemase as a target for drug discovery

S. Fisher, 2008, Microbial biotechnology.

Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers

L. Poling, R. Deibler, J. Yap, 2022, Cancer Research.

Altered recognition mutants of the response regulator PhoB: a new genetic strategy for studying protein-protein interactions.

C. Walsh, B. Wanner, A. Haldimann, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Biochemical characterization of an inhibitor of Escherichia coli UDP-N-acetylmuramyl-l-alanine ligase.

D. Ehmann, S. Fisher, K. Hull, 2004, Biochimica et biophysica acta.

Transcriptional regulation of the Enterococcus faecium BM4147 vancomycin resistance gene cluster by the VanS-VanR two-component regulatory system in Escherichia coli K-12

C. Walsh, B. Wanner, A. Haldimann, 1997, Journal of bacteriology.

Enzyme-Based Screens in HTS

David E. Ehmann, Stewart L. Fisher, D. Ehmann, 2012 .

Correlating drug–target kinetics and in vivo pharmacodynamics: long residence time inhibitors of the FabI enoyl-ACP reductase

C. Sotriffer, P. Tonge, C. Kisker, 2016, Chemical science.

Exploring Left-Hand-Side substitutions in the benzoxazinone series of 4-amino-piperidine bacterial type IIa topoisomerase inhibitors.

C. Eyermann, S. Fisher, F. Reck, 2011, Bioorganic & medicinal chemistry letters.

Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.

S. Steinbacher, P. Reinemer, S. Haggarty, 2016, Bioorganic & medicinal chemistry.

A quantitative mechanistic PK/PD model directly connects Btk target engagement and in vivo efficacy† †Electronic supplementary information (ESI) available: Derivation of PK/PD models, supplemental methods, analytical data. See DOI: 10.1039/c6sc03306g Click here for additional data file.

P. Tonge, S. Fisher, F. Daryaee, 2017, Chemical science.

Semisynthesis of bipyridyl-alanine cytochrome c mutants : novel proteins with enhanced electron-transfer properties

B. Imperiali, H. Gray, D. Wuttke, 1993 .

A Method for Determining the Kinetics of Small-Molecule-Induced Ubiquitination

D. Proia, R. Deibler, S. Fisher, 2021, SLAS discovery : advancing life sciences R & D.

(S)‐α‐Amino‐2,2′‐bipyridine‐6‐propanoic Acid: A Versatile Amino Acid for de Novo Metalloprotein Design.

B. Imperiali, S. Fisher, 1992 .

Chemoenzymic synthesis of 2-amino-3-(2,2'-bipyridinyl)propanoic acids

B. Imperiali, S. Fisher, T. Prins, 1993 .

Cross-talk between the Histidine Protein Kinase VanS and the Response Regulator PhoB

C. Walsh, B. Wanner, S. Fisher, 1995, The Journal of Biological Chemistry.

Abstract LB007: CFT7455: A novel, IKZF1/3 degrader that demonstrates potent tumor regression in IMiD-resistant multiple myeloma (MM) xenograft models

Christina M. Henderson, A. Good, D. Proia, 2021, Experimental and Molecular Therapeutics.

Kinetic comparison of the specificity of the vancomycin resistance VanSfor two response regulators, VanR and PhoB.

C. Walsh, B. Wanner, S. Fisher, 1996, Biochemistry.

Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers

S. Haggarty, L. Tsai, E. Scolnick, 2014, Chemical science.

Abstract 3425: The discovery and characterization of CFT1946: A potent, selective, and orally bioavailable degrader of mutant BRAF for the treatment of BRAF-driven cancers

M. Sowa, L. Poling, Yanke Liang, 2023, Cancer Research.

Avibactam is a covalent, reversible, non–β-lactam β-lactamase inhibitor

D. Ehmann, P. Ross, S. Fisher, 2012, Proceedings of the National Academy of Sciences.